Don’t tell Michelle Bachman, but trials of the new malaria vaccine developed by GlaxoSmithKline have met with great success: Final-stage trial data released on Tuesday showed it gave protection against clinical and severe malaria in five- to 17-month-olds in Africa, where the mosquito-borne disease kills hundreds of thousands of children a year. “These data bring us […]
Read more at Forbes.